Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

Por van Baarsen, Lisa G. M., Vosslamber, Saskia, Tijssen, Marianne, Baggen, Josefien M. C., van der Voort, Laura F., Killestein, Joep, van der Pouw Kraan, Tineke C. T. M., Polman, Chris H., Verweij, Cornelis L.
Publicado em 2008

T helper type 1 and 17 cells Determine Efficacy of IFN-β in Multiple Sclerosis and Experimental Encephalomyelitis

Por Axtell, Robert C., de Jong, Brigit A., Boniface, Katia, van der Voort, Laura F., Bhat, Roopa, De Sarno, Patrizia, Naves, Rodrigo, Han, May, Zhong, Franklin, Castellanos, Jim G., Mair, Robert, Christakos, Athena, Kolkowitz, Ilan, Katz, Liat, Killestein, Joep, Polman, Chris H., de Waal Malefyt, René, Steinman, Lawrence, Raman, Chander
Publicado em 2010